Top Markets
#1 Official Trump Official Trump +51.60%
#2 Movement Movement +32.33%
#3 Mubarak Mubarak +26.27%
#4 Pearl Pearl +24.49%
#5 Zama Zama +24.44%
#6 Melania Meme Melania Meme +22.38%
#7 EXOD EXOD +18.93%
#8 Wrapped POL Wrapped POL +18.74%
#9 POL (ex-MATIC) POL (ex-MATIC) +18.66%
#10 Wrapped STX (Velar) Wrapped STX (Velar) +16.92%
Coin of the day
Official Trump Official Trump
Ayarlar
Dil
TüRKçE
Para birimi
USD
Tema
Citius Oncology, Inc. Citius Oncology, Inc.

Citius Oncology, Inc.

CTOR
Hisse Senetlerindeki Sıralama #23802
Citius Oncology, Inc. concentrates on advancing innovative, targeted... Citius Oncology, Inc. concentrates on advancing innovative, targeted therapeutic solutions for various cancer types. A key aspect of its pipeline includes the development of LYMPHIR, an investigational orphan drug intended to treat adults battling cutaneous T-cell lymphoma that has either relapsed or is unresponsive to existing therapies. The firm's main offices are situated in New York, New York. Citius Oncology, Inc. functions as a division of its parent company, Citius Pharmaceuticals, Inc.
Hisse Fiyatı
$0.7426
Son senkronizasyon: 2026-08-21
Piyasa Değeri
$69.05M
Değişim (1 gün)
-2.17%
Değişim (1 yıl)
-57.57%
Ülke
US
Ticaret Citius Oncology, Inc. (CTOR)

Kategori

Healthcare
Citius Oncology, Inc. (CTOR) için temettü verimi geçmişi
Citius Oncology, Inc. (hisse sembolü: CTOR) temettü verimi (TTM) 2026 itibariyle: 0
Son 5 yılın ortalama temettü verimi: 0.00%
Citius Oncology, Inc. (CTOR) için 2026 - 2026 arası temettü verimi geçmişi
Her yılın sonunda temettü verimi (TTM)
Yıl Temettü Verimi Değiştir
Sağlanan tarihler için yeterli veri yok.
Benzer şirketler veya rakiplerin temettü verimi (TTM)
Şirket Temettü Verimi Ülke
Eli Lilly and Company Eli Lilly and Company
Eli Lilly and Company
LLY.US
0.57%
US
Johnson & Johnson Johnson & Johnson
Johnson & Johnson
JNJ.US
2.01%
US
AbbVie Inc. AbbVie Inc.
AbbVie Inc.
ABBV.US
2.74%
US
Roche Holding AG Roche Holding AG
Roche Holding AG
RO.SW
2.69%
CH
Merck & Co., Inc. Merck & Co., Inc.
Merck & Co., Inc.
MRK.US
2.47%
US